FDA Food and Drug Administration

FDA recalls thyroid medicine

Nationwide recall issued for this thyroid medication. See products

Major Rugby, a pharmaceutical manufacturer that produces levothyroxine sodium tablets, issued a nationwide recall for the common thyroid medication, according to a letter it sent to retailers earlier this month.

· 1h · on MSN

FDA recalls thyroid medication sold nationwide over potency concern

· 4h · on MSN

Thyroid medication recalled throughout US — see all the products affected

· 7h

Major Pharmaceuticals recalling levothyroxine tablets nationwide

Major Pharmaceuticals initiated a voluntary recall of its levothyroxine sodium tablets on July 13 after the Food and Drug Administration determined the pills were subpotent, meaning they deliver less ...

· 1d

FDA recalls levothyroxine sodium tablets. Here's what to know

· 1d

Thyroid medication described as 'subpotent drug' recalled by FDA

14don MSNOpinion

Trust in the FDA is collapsing. It’s time to get really transparent about our food and our drugs

Patients with no other options are watching an agency turn on its own scientists — and the trust that took a century to build is draining out in two years.

MEAT+POULTRY

FDA advances removal of two petroleum-based food dyes

The FDA began the process of removing Citrus Red No. 2 and Orange B from the nation’s food supply in April 2025. At that time, the FDA also said it intended to phase out all petroleum-based synthetic dyes from the nation’s food supply by the end of 2026 and planned to work with food and beverage companies to do so.

11h

Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration

FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission PRINCETON,

5don MSN

FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers

Federal health advisers are meeting to review more than a half-dozen peptides, unproven substances that have become a growing wellness trend despite little evidence they are safe or effective.

Agri-Pulse

FDA outlines 2026 food safety and nutrition priorities

The Food and Drug Administration's official priorities for food regulation in 2026 include overhauling the process for determining the safety of ingredients, and expanding the role of state agencies in food inspections. FDA on Friday released a long ...

FDA Reports a New Cyclospora Outbreak

The Food and Drug Administration is looking into a new outbreak of cyclospora linked to a not yet identified product and has initiated traceback. The new outbreak includes 72 cases. Government agencies have linked lettuce to thousands of reports of foodborne illness in the U.S.

Neurology Advisor

Simtriyo Gains FDA Approval as First NDSRI CNS Stimulant for ADHD

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.

‘Pandora’s box’: FDA peptide votes could open the door to more unproven drugs

An FDA panel with ties to the industry recommended loosening regulations on six peptides over objections from FDA scientists over a lack of data.

13don MSNOpinion

FDA drug approval affects healthcare around the world, but political shortcuts could hurt the agency’s international reputation

At the beginning of July 2026, the U.S. Food and Drug Administration approved the first gene therapy for young children with sickle cell disease. While this is good news for children in the U.S. born with this illness,

MPR

FDA Accepts NDA Resubmission for SL1009 in Rare Mitochondrial Disorder

Following an August 2025 CRL that raised no safety or manufacturing concerns, Saol provided additional survival analyses of existing clinical data to address FDA requirements without embarking on a new multi-year trial.